Roche to file Herceptin for stomach cancer after survival benefit shown in Phase III
This article was originally published in Scrip
Executive Summary
Roche/Genentech's HER2-targeted breast cancer drug Herceptin (trastuzumab) has improved overall survival in a first-line Phase III trial in a subset of patients with advanced gastric (stomach) cancer, and Roche told Scrip that it plans to file the drug for this new indication.